Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06470763 · ClinicalTrials.gov registry record · Phase 1

A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)

A Phase 1 study of Advanced Solid Tumor, sponsored by Anaveon.

Recruiting
Registry status
Phase 1
Development phase
240
Enrollment target
18
Study locations

NCT06470763 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Anaveon. The registered enrollment target is 240 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The trial reports 18 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06470763, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Anaveon.

RECRUITING
Registry status
Phase 1
Development phase
240 participants
Enrollment target
18
Study locations

Study Summary

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG ANV600
  • DRUG ANV600 + pembrolizumab (KEYTRUDA®)

Study Locations (18)

Other

  • Cliniques Universitaires Saint-Luc - Brussels
  • Institut Bergonie - Bordeaux
  • CEPCM - AP-HM Hopital de la Timone - Marseille
  • Oncopole Claudius Regaud, Toulouse - Toulouse
  • Institut Gustave Roussy - Villejuif
  • Charite Universitaetsmedizin Berlin - Berlin
  • Krankenhaus Nordwest - Institut für Klinisch-Onkologische Forschung (IKF) - Frankfurt
  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz - Mainz
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) - Amsterdam
  • Vall d'Hebron Institute of Oncology (VHIO) - Barcelona
  • START Madrid CIOCC - Madrid
  • Clinica Universidad de Navarra - Pamplona - Pamplona
  • INCLIVA Foundation - Valencia
  • Ente Ospedaliero Cantonale - Istituto Oncologico della Svizzera Italiana - Bellinzona
  • Cantonal Hospital St Gallen - Sankt Gallen

Michigan

  • Karmanos Cancer Institute - Detroit

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2024-07-01
Est. Completion 2028-02
Phase Phase 1

Sponsor

Anaveon

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06470763

The ClinicalTrials.gov registry entry for NCT06470763 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (25% higher). The listed sponsor is Anaveon, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which ANV600 is the first listed.

NCT06470763 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Other, Michigan, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06470763 about?

NCT06470763 is a clinical study titled "A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)". The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor activity of ANV600 administered as a single agent or in combination with pembrolizumab in adult participants with advanced solid tumors.

What is the current status of trial NCT06470763?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-07-01. Estimated completion is 2028-02.

What conditions does trial NCT06470763 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06470763?

The interventions under investigation include: ANV600 (DRUG), ANV600 + pembrolizumab (KEYTRUDA®) (DRUG).

Who is sponsoring clinical trial NCT06470763?

This trial is sponsored by Anaveon, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06470763 being conducted?

This trial has 18 study locations across Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.